ArticleThe Korean journal of internal medicine2026

A bridge, not a destination: clarifying the role of polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma.

No numbers read from the abstract.

Not cited yet